Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

novel antiplatelet agent that can potentially prevent the formation of deadly blood clots without adding a significant bleeding risk (in Phase III); approximately 13,000 patients have been enrolled in its Phase III program targeted to include 30,000 patients;
  • SIMPONI(TM)* (golimumab), a once-monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under review in EU for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside the U.S. except in Japan and certain other Asian markets;
  • SAPHRIS(TM)** (asenapine), a novel psychopharmacologic agent (under U.S. review for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder); pivotal relapse-prevention data were presented showing that only 12 percent of patients receiving asenapine relapsed at the specified endpoint versus 47 percent of patients receiving placebo;
  • BRIDION(R) (sugammadex), the first and only selective relaxant binding agent for reversing neuromuscular blockade in anesthesia (approved in EU; under review in U.S. and Japan);
  • Boceprevir, an oral protease inhibitor for treating hepatitis C with peginterferon and ribavirin combination therapy (in Phase III); 24-week sustained viral response (SVR) data were presented showing that 75 percent of patients achieved SVR; in addition, a next-generation protease inhibitor in Phase II for treating hepatitis C was unveiled, with the potential to offer once-daily dosing and having 10 times the in vitro potency of current protease inhibitors in late-phase development;
  • Mometasone furoate and formoterol (MFF), an inhaled combination therapy for asthma and COPD (completing Phase III); pivotal data from Phase III trials in asthma were presented showing that MFF met its primary endpoints; and
  • Preladenant, a nov
    '/>"/>

    • SOURCE Schering-Plough Corporation
    Copyright©2008 PR Newswire.
    All rights reserved

    5

    GOOD

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
    2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
    3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
    4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
    5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
    6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
    7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
    8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
    9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
    10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
    11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... 21, 2013 STAAR Surgical Company (NASDAQ: ... of minimally invasive ophthalmic products, today announced that it ... the Company,s recent financial results and business developments with ... present at the 38 th Annual Deutsche Bank ... at the Westin Waterfront Hotel on Wednesday, May 29, ...
    (Date:5/20/2013)... , May 21, 2013 ... Assembly, where world,s health ministers gather to address the ... Mental and neurological disorders (MNDs) affect 700 million ... non-communicable disease (NCD) burden ,Do You Mind?, ... the role each can play to collectively address MNDs ...
    (Date:5/20/2013)... , May 20, 2013 Landauer, Inc. ... personal and environmental radiation measurement and monitoring, outsourced medical ... today that its Board of Directors declared, at its ... dividend of $0.55 per share for the third quarter ... July 3, 2013, to shareholders of record on June ...
    Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Landauer, Inc. Declares Regular Cash Dividend 2
    ... dose of velafermin for the prevention ... path for belinostat in the ... treatment of cancer -, - Conference call and webcast to ... 6 CuraGen Corporation,(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on,oncology, ...
    ... with ... ImmuneRegen,s Adjuvant, SCOTTSDALE, Ariz., ... BioSciences Holdings, Inc.,(OTC Bulletin Board: IRBO), today announced it has ... VXGN.PK). As part,of the agreement, ImmuneRegen will receive the pharmaceutically ...
    Cached Medicine Technology:CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 2CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 3CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 4CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 5CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 6CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 7CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 8ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 2ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 3ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 4
    (Date:5/21/2013)... Puroast® Low Acid Coffee has named former Johnson ... the Board. , Among the many key ... his more than 30-year career was as a member ... of Consumer Pharmaceuticals & Nutritionals and President of McNeil ... build the market for such brands as Splenda®, Lactaid®, ...
    (Date:5/21/2013)... attack on glioblastoma brain tumor cells that uses a ... study to establish the proper dose level, researchers at ... Duke and tested in an ongoing phase 1 study, ... abundance of receptors that work like magnets drawing the ... , The investigational therapy, known as PVSRIPO, uses an ...
    (Date:5/21/2013)... 21, 2013 Adeptia, a leading provider ... today announced it is the featured company in an ... Research. The report, “Adeptia Bets on Converged Cloud Integration ... company, its strategy, products, pricing, customers and competition. ... a framework for integration and process orchestration, especially when ...
    (Date:5/21/2013)... , , TUESDAY, May 21 (HealthDay News) -- Depression can ... the changes brought about by the disorder can be ... has found that people with diabetes who are depressed ... having a severe low blood sugar (hypoglycemia) episode that ... diabetes who aren,t depressed. "Depression is a ...
    (Date:5/21/2013)... long been known for their health benefits, and ... like anti-cancer drugs are delivered to specific tumor ... how to create nanoparticles using natural lipids derived ... them as drug delivery vehicles. UofL scientists Huang-Ge ... team today (May 21, 2013), published their findings ...
    Breaking Medicine News(10 mins):Health News:Former Johnson & Johnson Executive Brian Perkins Named Chairman of Puroast® Coffee 2Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2
    ... to fund multiple sclerosis researchCHICAGO, April 6 The ... support for MS education and awareness by purchasing the ... March 4, 2009, the Lottery released "Dash! For Cash" ... For Cash" is the second instant game created to ...
    ... decision by the Centers for Medicare and Medicaid Services ... scans in the initial treatment strategy of patients with ... compelling clinical evidence of the effectiveness of PET for ... known as the National Oncologic PET Registry (NOPR). ...
    ... hopes for stem cell therapy, major structural and cultural changes ... in the UK. Currently the chances of getting effective treatments ... industry is at serious risk of ,market failure,. , These ... and adoption of stem cell therapy carried out by researchers ...
    ... Americans free and unique fitness tools to help reduce stress ... is a fact of life. However, with the declining economy ... stressed than ever and some are looking for solutions on ... honor of Stress Awareness Month, is offering people free and ...
    ... or fiber and other beneficial nutrientsGLENDALE, Calif., April 6 ... to benefit children during different stages of their growth ... Juice Immunity are fruit juice beverages made with ... filtered water to naturally lower the sugar and calorie ...
    ... Rating Based on Quality Accounting and ManagementFRANKLIN LAKES, ... wondering about the safety of their savings, Forbes ... MHS ) as one of "The 100 Most Trustworthy ... upon Audit Integrity,s ranking of corporate accounting and management ...
    Cached Medicine News:Health News:Illinois Lottery Releases New MS Ticket, Dash! For Cash 2Health News:Illinois Lottery Releases New MS Ticket, Dash! For Cash 3Health News:SNM calls CMS PET scan decision a major benefit for cancer patients 2Health News:SNM calls CMS PET scan decision a major benefit for cancer patients 3Health News:Stem cell innovation at risk 2Health News:Beat Stress for Free: MSN Encourages Americans to Take It Out on the Treadmill 2Health News:Beat Stress for Free: MSN Encourages Americans to Take It Out on the Treadmill 3Health News:Beat Stress for Free: MSN Encourages Americans to Take It Out on the Treadmill 4Health News:Beat Stress for Free: MSN Encourages Americans to Take It Out on the Treadmill 5Health News:From Early Brain Development to Digestive Health, New Juicy Juice Beverages Aid Children Through Different Stages of Growth and Development 2Health News:From Early Brain Development to Digestive Health, New Juicy Juice Beverages Aid Children Through Different Stages of Growth and Development 3Health News:From Early Brain Development to Digestive Health, New Juicy Juice Beverages Aid Children Through Different Stages of Growth and Development 4Health News:Forbes Counts Medco As One of The 'Most Trustworthy Companies' 2Health News:Forbes Counts Medco As One of The 'Most Trustworthy Companies' 3
    ... is a scientifically advanced nutritional formulation ... and full body health. MacularProtect Complete ... trial and other advanced research. It ... provides a broad foundation of antioxidants, ...
    ... OcularProtect is a scientifically ... support for visual and full ... 40 key nutrients, including a ... as FloraGLO lutein, lycopene and ...
    Ocuvite® Lutein is an advanced antioxidant supplement formulated to provide nutritional support for the eye....
    ... vitamins, minerals, and antioxidants in ... ocular tissue, improves tear quality, ... the lens and retina of ... optimized to bring accelerated relief ...
    Medicine Products: